comparemela.com

Latest Breaking News On - Great ape adenoviral - Page 1 : comparemela.com

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland, Jan. 5, 2023 /PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered

United statesEleanor perkinPrnewswire nouscomMarwang fakihRichard davisSylvie berrebiBristol myers squibbMarina udierMerck co incMerck sharp dohmeJanssen research developmentMicrosatellite instable highMetastatic colorectal cancerChief executive officerMerck sharpProfessor marwan

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an off-the shelf Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland, Nov. 15, 2022 /PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient

United statesEleanor perkinPrnewswire nouscomRick davisMarwang fakihSylvie berrebiBristol myers squibbMichaelj overmanMarina udierKostenloser wertpapierhandelUniversity of texas md anderson cancer centerDepartment of gastrointestinal medical oncologyJanssen research developmentMicrosatellite instable highPrincipal investigatorGastrointestinal medical oncology

Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an off-the-shelf Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

/PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced.

United statesEleanor perkinPrnewswire nouscomRick davisMarwang fakihSylvie berrebiMarina udierAmerican association for cancer researchAmerican society of clinical oncologyClinical oncologyAnnual meetingMicrosatellite instable highAmerican associationCancer researchMedical oncology specialistDuarte california

Nouscom to Present Full Phase 1 Data of NOUS-209, an off-the-shelf Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

/PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced.

United statesMarwan fakihEleanor perkinRick davisSylvie berrebiAmerican society of clinical oncologyClinical oncologyMicrosatellite instable highPresentation detailsMedical oncology specialistDuarte californiaGreat ape adenoviralModified vaccinia ankara

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an off-the-shelf Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

/PRNewswire/ Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced.

United statesEleanor perkinPrnewswire nouscomRick davisMarwang fakihSylvie berrebiElisa scarselliAmerican association for cancer researchSociety for immunotherapy of cancerLate breakingCancer researchMicrosatellite instable highAnnual meetingMedical oncology specialistDuarte californiaChief scientific officer

vimarsana © 2020. All Rights Reserved.